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Objective. The Affordable Care Act mandates the Prospective Payment System (PPS)-Exempt Cancer Hospitals
Quality Reporting program. These 11 hospitals (which are paid fee-for-service rather than on a DRG system)
began reporting measures (2 general safety, 2 breast, 1 colon) in 2013. Given this reporting mandate, we set out
to determine whether the PPS-exempt gynecologic oncology programs could identify quality measures speciﬁc to
the care of our patients.
Methods. A list of 12 quality measures speciﬁc to gynecologic oncology was created (from sources including
the National Quality Forum and the SGO). Measures already in use were not included. The list was ranked by the
gynecologic oncology program directors at the PPS-exempt hospitals. Descriptive statistics (including mean and
SD for rankings) were utilized.
Results. Despite mandatory reporting of quality measures for PPS-exempt cancer hospitals, little consensus
exists regarding speciﬁc gynecologic cancer measures. Documentation of debulking status, cancer survival, and
offering minimally invasive surgery (for endometrial cancer) and intraperitoneal chemotherapy (for ovarian
cancer) are important, but with widely variable responses (when ranked 1–12, standard deviations are 2–3).
General issues regarding adherence to guidelines for the use of GCSF, documentation of functional status,
and tracking of patient satisfaction scores were ranked the lowest. Three of the directors reported that their
compensation is partially linked to quality outcomes.
Conclusions. There is wide variability in ranking of quality measures, andmay relate to provider or institutional
factors. Despite the mandatory reporting in PPS-exempt cancer hospitals, work remains to deﬁne gynecologic
cancer quality measures.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.0 Starling Loving Hall, Columbus, OH 43210, USA. Fax: +1 614 366 7942.
.
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Oncology 130 (2013) 403–406IntroductionWhile tempting to assume that the substantial increased spending on
health care (projected to reach $4.5 trillion by 2020 from $2.5 trillion in
2009) leads to improved quality in the delivery and outcomes, this corre-
lation has not been demonstrated [1]. In an effort to improve the corre-
lation between health care spending and quality, the Department of
Health andHumanServices (HHS)was directed by the Patient Protection
andAffordable Care Act (PPACA, otherwise known as the ACA, enacted in
March 2010) to expand its use of health care qualitymeasures (including
expanding its pay-for-performance programs). Despite the mandate for
the implementation of quality measures by HHS, the process by which
quality measures are identiﬁed, vetted, demonstrated and implemented
is complex and continues to evolve. Mandatory reporting of quality
measures was included in the ACA (section 2701), and in January 2012,
the HHS announced the initial set of health care quality measures for
Medicaid-eligible adults. These measures were evaluated by the Agency
for Healthcare Research and Quality (AHRQ), and endorsed by the
National Quality Forum (NQF, whose membership includes more than
400 organizations that represent health care providers, consumers, and
researchers) [2]. Cancer measures were excluded from this group, since
the ACA provided guidance on cancer quality measures separately in
the Medicaid Quality Measurement Program (MQMP).
In patients with cancer, the ACA (section 3005) utilizes the free-
standing cancer hospitals to be responsible for reporting cancer-
speciﬁc quality measures. In 1983, Congress developed a system
(deﬁned as the Prospective Payment System, PPS) to control hospital
costs charged to Medicare (now Centers for Medicare & Medicaid
Services, CMS), but provided free-standing cancer hospitals an ex-
emption to this system given their higher than average costs overall.
While most care (including cancer care) is reimbursed as cumulative
amount based on a “disease-related group” (DRG) payment, 11 free-
standing cancer hospitals are paid on a fee-for-service basis (and
are thus considered Prospective Payment System (PPS)-exempt).
These 11 PPS-exempt cancer hospitals were required by the ACA to
participate in the Prospective Payment System (PPS)-Exempt Hospitals
Quality Reporting (PCHQR) program for cancer discharges, which
mandates the public reporting of quality data in ﬁscal year 2014. The
reporting period for the 2014 PCHQR began on January 1, 2013. Thus,
the 11 PPS-exempt cancer hospitals began reporting 5 quality mea-
sures, which include two CDC National Health Safety Network health
care associated infection outcome measures, one process of care mea-
sure for colon cancer, and two process of care measures for different
types of breast cancer (Table 1), all of which are endorsed by the NQF.
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Five quality measures that Prospective Payment System (PPS)-exempt cancer hospitals
were mandated by PCHQR to report in January 2013.
1. Cross-cutting (general) measures
a. NHSN Central-Line Associated Blood Stream Infection (CLABSI) measure
(NQF #0139)
b. NHSN Catheter-Associated Urinary Tract Infection (CAUTI) measure (NQF #0138)
2. Breast cancer measures
a. Combination chemotherapy is considered or administered within 4 months
(120 days) of diagnosis to women b70 with AJCC T1c or Stage II or III hormone
receptor negative breast cancer (NQF #0559)
b. Adjuvant hormonal therapy (tamoxifen or third generation aromatase inhibitor)
is considered or administered within one year of diagnosis to women over 18
with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast cancer
(NQF #0220)
3. Colon cancer measure
a. Colon cancer: adjuvant chemotherapy is considered or administered with
4 months (120 days) of surgery to patients b80 with AJCC T1c (lymph node
positive) colon cancer (NQF #0223)
Abbreviations: PCHQR, PPS-Exempt Cancer Hospitals Quality Reporting; PPS, Prospective
Payment System; NHSN, National Healthcare Safety Network; NQF, National Quality
Forum; AJCC, American Joint Committee on Cancer.Given the early requirement for and familiarity with reporting
quality measures by the 11 PPS-exempt cancer hospitals, we set out
to determine whether the directors of the gynecologic oncology pro-
grams in the PPS-exempt cancer hospitals could agree upon reasonable
and appropriate quality measures speciﬁc to the care of women with
gynecologic cancers.
Methods
Given the absence of gynecologic cancer speciﬁc quality measures
endorsed by the NQF, a list of 12 potential quality measures speciﬁc to
the specialty of gynecologic oncology was developed by two of the
authors (DEC and BAG). These quality measures were derived from
a variety of sources, including some which were endorsed by the
NQF (for general oncology), some ovarian cancer speciﬁc measures
that were developed jointly between the Society of Gynecologic
Oncology (SGO) and the American Society of Clinical Oncology
(ASCO) as part of the ASCO Quality Outcome Practice Initiative (QOPI)
but not yet endorsed by the NQF [3], and others from the Quality and
Outcomes Committee of the SGO (Table 2). Measures already in use
(for example, from the Physician Quality Reporting System (PQRS))
like perioperative antibiotic or thromboembolic prophylaxis were not
included. In general, the selection of measures were chosen to span
the most common gynecologic malignances, to account for the indi-
cators that differentiates care provided to patients with gynecologic
cancers, and to cover some general oncology measures that have
been adopted by other organizations. This list was not meant to be
comprehensive; it was designed to attempt to understand the factors
that gynecologic oncologists believe deﬁne quality.
The compiled list was distributed to the directors or their designee
(herein called “directors”, all of whom are gynecologic oncologists)
of gynecologic oncology programs at the 11 PPS-exempt hospitals
(Table 3). Directors were asked to rank the measures (with 1 being
the “best” measure and 12 being the “worst” measure) without any
speciﬁc guidance as to how this should be accomplished. There was
no discussion amongst directors and speciﬁcally, these individuals
were not explicitly asked to consider the origin of the measures,
their complexity or feasibility of data collection, the reproducibility of
these measures, or their implications on measuring quality outcomes.
Recommendations for other measures not included in the initial list
were also solicited. Descriptive statistics (including mean and SD for
rankings) were utilized.
Results
Of the 12 quality measures distributed to the directors of gyneco-
logic oncology programs at the PPS-exempt cancer hospitals, there
was a wide variability in the rankings between directors (Table 4).
The quality measure ranked most highly (had the lowest ranking
score) had a mean score of 3, with a standard deviation of 2.6. The
measure that ranked lowest (had the highest score) had a mean
score of 8.6, with a standard deviation of 2.8. The standard deviations
ranged from 2.4 to 3.8, demonstrating a lack of agreement about
the “best” measure in determining quality gynecologic cancer care.
Despite this apparent lack of consensus, certain trends were apparent.
When the distributed quality measures were considered based on the
component of care responsible for assessment of the measure, it was
more common for measures under the control of a provider (such as
the documentation of residual disease after ovarian cancer surgery or
offering minimally invasive surgery for endometrial cancer) to rank
more highly than measures primarily determined by forces outside
of the provider (such as patient satisfaction) or generally provided
by other non-physician clinical staff (such as documentation of
functional status or pain, Table 5). While the overall number of mea-
sures was limited, it seems that measures focusing on a speciﬁc ma-
lignancy were more highly ranked than general oncology measures
Table 2
Proposed quality measures that impact gynecologic cancer care (listed alphabetically).
1. Debulking: documentation of debulking status (optimal versus suboptimal)
in the operative note of a patient undergoing surgery for advanced ovarian cancer
2. Function: documentation of functional status at every outpatient encounter
3. GCSF: adherence to ASCO guidelines for the use of GCSF in the prevention
of chemotherapy-induced neutropenia
4. Hospice: documentation of discussion of or referral to hospice within 30 days
of death
5. Intraperitoneal: documentation of discussion of intraperitoneal chemotherapy
for patients with advanced ovarian cancer
6. Minimally invasive surgery: documentation of a discussion regarding the
possibility of minimally invasive surgery for the surgical management of clinical
stage I–II endometrial cancer (including documentation of offer for referral to a
provider who performs this surgery)
7. Pain: documentation of pain status at every outpatient encounter
8. Readmission: readmission of gynecologic cancer patients within 30 days
of discharge
9. Referral: documentation of referral to or consultationwith a gynecologic oncologist
consistent with ACOG/SGO committee opinion for the “role of the generalist
obstetrician–gynecologist in the early detection of ovarian cancer”
10. Satisfaction: patient satisfaction scores are reviewed and tracked at the provider
level
11. Survival: gynecologic cancer survival is tracked by stage
12. Tumor board: discussion of all gynecologic cancer cases at multi-disciplinary
tumor board
Table 4
Ranking of quality measures in Prospective Payment System (PPS)-exempt cancer
programs (sorted alphabetically by name of quality measure), with hospital names
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measures, Table 5). Furthermore, there were four measures suggested
by the directors (which were not initially provided to the directors for
their consideration); two were cervical cancer speciﬁc and
provider-focused (offering fertility-sparing surgery and documenting
the recommendation for concurrent chemotherapy with radiation),
while the other two were general oncology measures (perioperative
morbidity and progression-free survival).
Given that each of the divisions of gynecologic oncology at the
PPS-exempt cancer hospitals are in academic settings, no associations
can be drawn about the impact of physician practice type on the rank-
ings of quality measures. However, three of the 11 directors reported
that the compensation of their faculty is at least partially linked
to quality outcomes (including patient satisfaction scores, rate of
thromboembolism prophylaxis, and on-time operating room starts).
Again, given the small sample size, the impact of a speciﬁc remuner-
ation system on the ranking of quality measures cannot be assessed.
Across all of the 11 hospitals, the percent Medicare beneﬁciaries
that make up their gynecologic oncology practice ranged from 5 to
60% (average 40%), thereby limiting the ability to draw conclusions
as to the impact of patient insurance status on the ranking of quality
measures.
Discussion
Despite the mandate for PPS-exempt cancer hospitals to report
quality measures on January 1, 2013, there is wide variability in
institutional ranking of quality measures, and may relate to provider
or institutional factors. While there are no speciﬁc gynecologic cancerTable 3
Prospective Payment System (PPS)-exempt cancer hospitals (listed alphabetically).
1. City of Hope (Duarte, CA)
2. Dana-Farber Cancer Institute (Boston, MA)
3. Fox Chase Cancer Center (Philadelphia, PA)
4. Fred Hutchinson Cancer Research Center (Seattle, WA)
5. MD Anderson Cancer Center (Houston, TX)
6. Memorial Sloan-Kettering Cancer Center (New York, NY)
7. Roswell Park Cancer Institute (Buffalo, NY)
8. Ohio State University James Cancer Hospital (Columbus, OH)
9. University of Miami Sylvester Cancer Center (Miami, FL)
10. University of Southern California Norris Cancer Center (Los Angeles, CA)
11. University of South Florida H. Lee Mofﬁtt Cancer Center (Tampa, FL)quality measures endorsed by the National Quality Forum to date,
there will be increasing importance on the development, validation
and implementation of such measures in the future. Currently, the
only measures to distinguish quality surgical care for gynecologic
cancer patients are appropriate thromboembolic and antibiotic pro-
phylaxis. The Affordable Care Act (ACA) has mandated the reporting
of cancer quality measures by the 11 PPS-exempt cancer hospitals
for ﬁscal year 2014, and the expectation will be that this will extend
beyond these select institutions soon thereafter. Given the rapid ex-
pansion of cost of healthcare without a commensurate improvement
in the quality of the care delivered, attention to the deﬁnition of qual-
ity is imperative if payment for cancer care will eventually be tied to
performance. In fact, the ACA required that 1% of Medicare hospital
payments be withheld in ﬁscal year 2012 under pay for performance
in the Medicare Value-Based Purchasing Program; this withholding
will rise to 2% by 2017 (increasing by 0.25% per year) and will be
used to reward hospitals for the quality of the care they provide to
Medicare beneﬁciaries [4]. Given that a pay for performance strategy
was shown to decrease mortality in England [5], expansion of such
initiatives in the United States is expected to be forthcoming. While
generic quality measures are easy to report, they do not explicitly
represent opportunities for improvements in cancer care especially
for the gynecologic cancer population [6]. As such, participation in
quality improvement programs such as the Center for Medicare
& Medicaid Services (CMS) Physician Quality Reporting (PQRS), the
American Society of Clinical Oncology (ASCO) Quality Oncology
Practice Initiative (QOPI), and the American College of Surgeons (ACS)
National Surgical Quality Improvement Program (NSQIP) may have
overall beneﬁts in quality improvement, but may not be entirely rele-
vant to practice in gynecologic oncology. Given the fact that outcomes
in ovarian cancer are directly related to surgeon experience and higher
hospital volume [7,8], deﬁning, validating and receiving NQF endorse-
ment for measures of quality ovarian cancer care are critical. Given
that it is estimated that more than half of all ovarian cancer patients
receive care from less-experienced surgeons and lower-volume hospi-
tals, timely identiﬁcation of such quality measures may lead to more
women receiving adequate ovarian cancer care, resulting in improved
outcomes.
The development of qualitymeasures for gynecologic cancers is cur-
rently in its infancy. The Society of Gynecologic Oncology has several
ongoing quality and outcome improvement initiatives with organiza-
tions dedicated to health care quality, and speciﬁc gynecologic cancer
measures (such as cost, surgical and perioperative complications and
morbidity, toxicity associated with non-surgical treatments, patient
satisfaction, and survival) are being developed and tested [3]. The
recent SGO Practice Summit entitled “We need a new paradigm in gy-
necologic cancer care: SGO proposes solutions for delivery, quality
and reimbursement policies” [9] highlights the importance of the devel-
opment of quality measures speciﬁc to the practice of gynecologicremoved.
A B C D E F G H I J K
Debulking 1 1 8 2 2 1 1 6 1 7 3
Functional status 8 11 9 10 12 11 11 4 9 3 10
GCSF 3 12 11 7 11 12 12 7 10 6 6
hospice 7 9 3 8 7 7 9 3 11 10 7
Intraperitoneal 4 7 9 1 6 2 7 12 4 8 2
MIS 2 4 6 3 3 4 4 2 5 11 11
Pain 9 10 2 9 10 5 10 11 3 2 8
Readmission 10 8 7 12 8 9 8 1 6 4 9
Referral 11 2 10 6 1 6 2 10 8 12 4
Satisfaction 6 5 5 11 5 8 5 9 7 5 12
Survival 5 3 1 5 4 3 3 8 12 1 1
Tumor board 12 6 4 4 9 10 6 5 2 9 5
Table 5
Rankings, perspective of, and diseases reﬂected in the quality measures suggested to
PPS-exempt gynecologic cancer programs (sorted by rank (mean score)).
Mean Median SD Perspective Disease
Debulking 3.00 2 2.68 Provider Ovary
Survival 4.18 3 3.34 Provider General
MIS 5.00 4 3.19 Provider Endometrial
Intraperitoneal 5.64 6 3.38 Provider Ovary
Tumor board 6.55 6 3.05 Provider General
Referral 6.55 6 3.93 Clinic General
Satisfaction 7.09 6 2.59 Clinic General
Pain 7.18 9 3.49 Referral Ovary
Hospice 7.36 7 2.54 Division General
Readmission 7.45 8 2.98 Patient General
GCSF 8.82 10 3.12 Patient General
Functional status 8.91 10 2.91 Provider General
Abbreviation: SD, standard deviation.
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cer registry to begin collecting the data necessary for more robust iden-
tiﬁcation of indicators of quality that can be utilized for future
benchmarking. Currently, the SGO quality and outcomes committee is
evaluating potential quality measures in endometrial, ovarian and cer-
vical cancers that will be tested in the future. The process of selecting
potential measures has been based on that used by the NQF Steering
Committee and Technical panels, which used four criteria: importance
(the extent to which a measure reﬂects variation and thus has the po-
tential for improvement), scientiﬁc acceptability (a measure that is
reliable, valid, precise, and adaptable to patient preference), usability
(ensuring that information produced as part of the measure could
be used to make decisions and/or take actions) and feasibility
(conﬁrming that data can be obtained within normal clinical care
and that implementation of the measure is achievable).
Given that the qualitymeasures ranked in this studywere evaluated
only by academic practices in PPS exempt cancer hospitals, no conclu-
sions can be drawn as to the impact of physician practice on the impor-
tance of speciﬁc qualitymeasures. In addition, the ﬁnding that directors
of gynecologic oncology programs at these hospitals ranked measures
under the control of the providermore highly than others cannot be gen-
eralized to indicate that these types of measures should be evaluated for
potential endorsement in the future. These results do, however, highlight
the importance of beginning the conversation about quality gynecologiccancer care within the specialty, and the need to be fully engaged in
thinking about the factors that contribute to the delivery of quality
care. In summary, while the importance of quality gynecologic cancer
care is widely recognized as the means by which patients will receive
optimal care, the current state of knowledge regarding the speciﬁc
measures that are important to gynecologic oncologists is less clear.
Despite mandatory reporting of some quality measures by PPS-exempt
cancer hospitals, it is imperative that discussions amongst providers of
gynecologic cancer continue towards the creation of national registries
that can begin to deﬁne important quality measures.Conﬂict of interest statement
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